Skip to main content
Premium Trial:

Request an Annual Quote

Nucleic Acid World Summit, New York Academy of Sciences, EuroForum International, Intradigm

Premium

NAWS Set for September in Boston

The Nucleic Acid World Summit is to be held on Sept. 15 -17 at the Radisson Hotel in Boston.

The event will feature more than 65 speakers from 60 different companies. Topics to be covered include siRNAs, antisense, ribozymes, alternative splicing/RNA trans-splicing, intellectual property, and investment trends.

Details about the conference can be found at http://www.srinstitute.com/part_iter_site_page.cfm?iteration_id=550.


NYAS’ First RNAi Symposium Date, Keynote Speaker Roster Finalized

The New York Academy of Sciences has scheduled its first half-day RNAi symposium for Oct. 27, at Rockefeller University’s Caspary Hall.

The meeting will begin at 2 pm and includes keynote presentations by MIT’s Phillip Sharp on the biology and possible uses of siRNAs and by Cenix Biosciences’s Chris Echeverri on the “art of genome-wide RNAi.”

The symposium will also feature talks by four New York-area researchers, who will be determined by abstract submission.

Information on registering to attend the meeting can be found at www.nyas.org. Abstract submitted for consideration must be sent to [email protected] and received by Sept. 25.


EuroForum RNAi Conference scheduled for Mid-November

EuroForum International is holding an RNAi conference on November 17 and 18 that will bring together representatives of both the drug industry and academic institutions to discuss the technology, its current uses, and barriers to its future development.

The conference will be held in central London at a venue yet to be confirmed. Speakers will include Chris Echeverri, of Cenix BioScience; Michal Janitz, of the Max Planck Institute for Molecular Genetics; and Andrew Clifton, from AstraZeneca.

Details about the event, including registration and pricing, can be found at http://www.ef-international.co.uk/index.cfm?conference=2333.


Intradigm Develops siRNA Inhibitor of SARS

Intradigm announced that it had developed siRNA capable of achieving 90 percent inhibition of the SARS virus in cell-based studies.

The company collaborated with Qiagen to design the siRNA, which targeted specific genes throughout the SARS genome. Qiagen synthesized the siRNA, and the product was tested in laboratories in Hong Kong and Guangzhou, China, using non-human primate cells exposed to the SARS virus.

The effort was sponsored by Hong Kong’s Top Biotech and the provincial government of Guangdong.

 

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.